Zim Corp
ZIM Corporation operates in the biomedical and emerging technology companies. It focuses on developing intellectual property, and research and development in the areas of new synthetic drugs and Immunotherapies. The company also offers spherical metal powders for additive manufacturing; and develops novel biomaterial for regenerative medicine. ZIM Corporation was founded in 1997 and is headquarte… Read more
Zim Corp (ZIMCF) - Net Assets
Latest net assets as of September 2021: $1.00 Million USD
Based on the latest financial reports, Zim Corp (ZIMCF) has net assets worth $1.00 Million USD as of September 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.07 Million) and total liabilities ($68.57K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.00 Million |
| % of Total Assets | 93.6% |
| Annual Growth Rate | 43.43% |
| 5-Year Change | 42.33% |
| 10-Year Change | -52.85% |
| Growth Volatility | 95609.44 |
Zim Corp - Net Assets Trend (2002–2021)
This chart illustrates how Zim Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zim Corp (2002–2021)
The table below shows the annual net assets of Zim Corp from 2002 to 2021.
| Year | Net Assets | Change |
|---|---|---|
| 2021-03-31 | $1.14 Million | -7.92% |
| 2020-03-31 | $1.23 Million | -10.74% |
| 2019-03-31 | $1.38 Million | +84.34% |
| 2018-03-31 | $749.90K | -6.06% |
| 2017-03-31 | $798.24K | -10.50% |
| 2016-03-31 | $891.93K | -25.05% |
| 2015-03-31 | $1.19 Million | -30.26% |
| 2014-03-31 | $1.71 Million | -20.78% |
| 2013-03-31 | $2.15 Million | -10.61% |
| 2012-03-31 | $2.41 Million | +14.90% |
| 2011-03-31 | $2.10 Million | +47.01% |
| 2010-03-31 | $1.43 Million | +83.55% |
| 2009-03-31 | $777.19K | +30.57% |
| 2008-03-31 | $595.22K | +121.33% |
| 2007-03-31 | $268.93K | -41.16% |
| 2006-03-31 | $457.02K | -86.58% |
| 2005-03-31 | $3.40 Million | -32.05% |
| 2004-03-31 | $5.01 Million | +417402.33% |
| 2002-03-31 | $1.20K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zim Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2127027800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2021)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $19.49 Million | 1715.63% |
| Other Comprehensive Income | $-42.10K | -3.71% |
| Other Components | $2.97 Million | 261.07% |
| Total Equity | $1.14 Million | 100.00% |
Zim Corp Competitors by Market Cap
The table below lists competitors of Zim Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Synthesis Energy Systems Inc
PINK:SYNE
|
$157.00 |
|
SANTANDER UK 8 5/8% NON-CUM STLG PRF
LSE:SANB
|
$157.33 |
|
India Capital Growth Fund
LSE:IGC
|
$157.46 |
|
HPI AG
MU:CEW3
|
$157.80 |
|
RA International Group
LSE:RAI
|
$156.58 |
|
CHINA DAYE NON-FERR
BE:TFTB
|
$156.51 |
|
Nostra Terra Oil and Gas Company PLC
LSE:NTOG
|
$156.42 |
|
SHORE GOLD
BE:GOC
|
$155.95 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zim Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2020 to 2021, total equity changed from 1,233,892 to 1,136,133, a change of -97,759 (-7.9%).
- Net loss of 76,568 reduced equity.
- Other comprehensive income increased equity by 550,813.
- Other factors decreased equity by 572,004.
Equity Change Factors (2020 to 2021)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-76.57K | -6.74% |
| Other Comprehensive Income | $550.81K | +48.48% |
| Other Changes | $-572.00K | -50.35% |
| Total Change | $- | -7.92% |
Book Value vs Market Value Analysis
This analysis compares Zim Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.33x to 0.00x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-03-31 | $0.00 | $0.00 | x |
| 2004-03-31 | $2.29 | $0.00 | x |
| 2005-03-31 | $1.17 | $0.00 | x |
| 2006-03-31 | $0.15 | $0.00 | x |
| 2007-03-31 | $0.06 | $0.00 | x |
| 2008-03-31 | $0.13 | $0.00 | x |
| 2009-03-31 | $0.16 | $0.00 | x |
| 2010-03-31 | $0.25 | $0.00 | x |
| 2011-03-31 | $0.34 | $0.00 | x |
| 2012-03-31 | $0.38 | $0.00 | x |
| 2013-03-31 | $0.33 | $0.00 | x |
| 2014-03-31 | $0.25 | $0.00 | x |
| 2015-03-31 | $0.17 | $0.00 | x |
| 2016-03-31 | $0.12 | $0.00 | x |
| 2017-03-31 | $0.10 | $0.00 | x |
| 2018-03-31 | $0.09 | $0.00 | x |
| 2019-03-31 | $0.17 | $0.00 | x |
| 2020-03-31 | $0.15 | $0.00 | x |
| 2021-03-31 | $0.14 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zim Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.02x
- Recent ROE (-6.74%) is above the historical average (-87.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -33.38% | -79.38% | 0.31x | 1.35x | $-2.17 Million |
| 2005 | -116.44% | -98.34% | 0.69x | 1.71x | $-4.30 Million |
| 2006 | -741.43% | -94.25% | 1.55x | 5.09x | $-3.43 Million |
| 2007 | -719.96% | -88.20% | 1.83x | 4.47x | $-1.96 Million |
| 2008 | 13.87% | 3.99% | 1.78x | 1.95x | $23.01K |
| 2009 | 19.75% | 8.38% | 1.58x | 1.49x | $75.79K |
| 2010 | 21.36% | 19.08% | 0.87x | 1.28x | $162.11K |
| 2011 | 17.49% | 19.18% | 0.78x | 1.17x | $157.08K |
| 2012 | 18.72% | 25.08% | 0.68x | 1.10x | $210.08K |
| 2013 | -9.33% | -15.34% | 0.54x | 1.14x | $-416.43K |
| 2014 | -20.59% | -27.63% | 0.61x | 1.21x | $-521.99K |
| 2015 | -19.89% | -20.85% | 0.76x | 1.25x | $-355.75K |
| 2016 | -34.94% | -50.33% | 0.58x | 1.19x | $-400.87K |
| 2017 | -8.70% | -10.35% | 0.71x | 1.18x | $-149.27K |
| 2018 | -5.72% | -8.53% | 0.60x | 1.12x | $-117.89K |
| 2019 | 50.89% | 100.50% | 0.46x | 1.11x | $565.28K |
| 2020 | -0.73% | -2.59% | 0.26x | 1.08x | $-132.39K |
| 2021 | -6.74% | 0.00% | 0.00x | 1.02x | $-190.18K |
Industry Comparison
This section compares Zim Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zim Corp (ZIMCF) | $1.00 Million | -33.38% | 0.07x | $156.96 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |